【作者】 郭英君；

【导师】 常占杰；

【作者基本信息】 陕西中医学院 ， 中医内科学， 2007， 硕士

【摘要】 目的:观察柔木丹颗粒治疗气虚血瘀瘀毒型慢性乙型肝炎肝纤维化的临床疗效以及对血清HA、LN、CⅣ、PCⅢ的影响,长期治疗的安全性,并初步探讨其作用机理。方法:临床选择符合纳入标准的气虚血瘀瘀毒型慢性乙型肝炎肝纤维化患者78例,随机分为两组,治疗组(40例)给予柔木丹颗粒口服,对照组(38例)给予复方鳖甲软肝片口服,疗程均为半年,观察两组患者治疗前后症状,体征,肝功能以及肝纤维化指标等。结果:临床研究显示,治疗组总有效率为80%,临床疗效与对照组差异无统计学意义(P>0.05);治疗组对乏力、腹胀、食欲不振、面色晦暗等症状、体征有明显的改善作用;肝功能治疗前后比较,治疗组ALT、AST、TBIL显著降低,治疗后两组ALT、AST组间比较有统计学意义(P<0.05);治疗后,治疗组与对照组HA、LN、PCⅢ、ⅣC均显著下降,但两组比较差异无统计学意义(P>0.05)。结论:对于气虚血瘀瘀毒型慢性乙型肝炎患者,柔木丹颗粒与复方鳖甲软肝片抗肝纤维化的疗效相近。但柔木丹颗粒同时对于肝损伤具有一定的保护作用,对于临床症状、体征的改善作用显著。更多还原

【Abstract】 Objective: To observe the clinical effect of the Roumudan Keli in treating chronic hepatitis B with Qi asthenia blood stasis and toxic retention, the influence on HA, LN, CⅣ, PCⅢ, the security of the long-term treatment. And to explore its mechanism of action preliminary.Methods:78 patients of chronic hepatitis B with Qi asthenia blood stasis and toxic retention were randomly divided into the treated group (40 cases), control group (38 cases), treated with the Roumudan Keli, FFBJRGP respectively, with half a year course, to observe the items of clinical symptoms, physical signs, hepatic function, and the serum fibrosis indexes.Result: The results showed that the total effective rate was 80% in the treated group after treatment, and clinical effect was no significant with control group(P>0.05);Clinical symptoms and physical signs, as follows debilitation, abdominal distention, anepithymia, dim complexion etc, were improved markedly in the treated group; Pre-and post-treatment the indexes of hepatic function were compared, the level of the serums ALT, AST, TBIL of the treated group decreased obviously, and there was significant between two groups on ALT, AST (P<0.05); After treatment, HA, LN, PCⅢ,ⅣC of the treated group and the control group decreased significantly, however there was no statistical significance between them (P>0.05).Conclusion: To the patients of chronic hepatitis B with Qi asthenia blood stasis and toxic retention, there is alike curative effect on Roumudan Keli therapy and FFBJRGP therapy in resisting hepatic fibrogenesis. However the Roumudan Keli possess the function of protecting the hepatic cells, and the function of ameliorating Clinical symptoms and physical signs of the Roumudan Keli therapy are better than the FFBJRGP therapy.更多还原